PUBLISHER: The Business Research Company | PRODUCT CODE: 1270541
PUBLISHER: The Business Research Company | PRODUCT CODE: 1270541
“Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The non-alcoholic steatohepatitis (nash) market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Major players in the non alcoholic steatohepatitis (nash) market are AstraZeneca plc., Arena Pharmaceuticals Inc., GSK plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Vivus LLC, Arisaph Pharmaceuticals Inc., Cempra Pharmaceuticals Inc., Galectin Therapeutics Inc., Galmed Pharmaceuticals Inc., Genfit SA, Gilead Sciences Inc., Immuron Limited, Raptor Pharmaceutical Inc., The Takeda Pharmaceutical Company Limited, Tobira Therapeutics Inc., VERVA Technologies Pvt. Ltd., Viking Therapeutics, Cadila Pharmaceuticals Ltd., Novartis AG, Conatus Pharmaceuticals Inc., One Way Liver S.L., and BioPredictive S.A.S.
The global non alcoholic steatohepatitis (NASH) market is expected to grow from $2.42 billion in 2022 to $3.25 billion in 2023 at a compound annual growth rate (CAGR) of 34.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The non alcoholic steatohepatitis (NASH) market is expected to grow to $10.73 billion in 2027 at a CAGR of 34.7%.
The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of nonalcoholic fatty liver diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure.
North America was the largest region in the non alcoholic steatohepatitis (NASH) market in 2022. The regions covered in the non alcoholic steatohepatitis (NASH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main types of non-alcoholic steatohepatitis (NASH) are solid and liquid. Solid is primarily created as crystalline solid forms that are sold as tablets for oral consumption, due to its excellent purity and durability. The products involved are vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib, and cenicriviroc, and others that are used for different disease causes such as hypertension, heart disease, high blood lipid, type 2 diabetes, obesity, and sold by the hospital pharmacy, retail pharmacy, online providers. It includes oral and parenteral applications.
The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As nonalcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in April 2021, according to the COVID-19 and Obesity: The 2021 Atlas, a report published by the World Obesity Federation, a UK-based federation that represents professional members of the scientific 2021, percentage of overweight adults recorded more than 60% of the US population, however, the obesity percentage of male expected to reach 44.2% and female 44.4% by 2025 in the US population. Therefore, the rise in the cases of obesity will drive the growth of the Non-Alcoholic Steatohepatitis (NASH) market.
Technological advancement is a key trend gaining popularity in the non-alcoholic steatohepatitis (NASH) market. Major players in the non-alcoholic steatohepatitis (NASH) market are focused on technological advancement to sustain their marketplace. For instance, in May 2021, GENFIT Inc., a France-based biotechnology company launched NASHnext, a brand-new non-invasive test for diagnosing non-alcoholic steatohepatitis (NASH). NIS4TM, a GENFIT-exclusive screening technology that uses a revolutionary blood-based molecular biomarker test to detect NASH and severe fibrosis, powers NASHnext. The test is only made available in the United States and Canada by Labcorp, one of the top worldwide life sciences businesses.
In July 2022, Advanz Pharma Corp. Limited, a UK-based pharmaceutical company acquired Intercept Pharmaceuticals Inc for an undisclosed amount. With this deal, Advanz Pharma aims to have a significant presence in the treatment of rare diseases by including the ex-U.S. rights to the orphan medicine Ocaliva (obeticholic acid), which is used to treat primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc is a US-based biopharmaceutical company focused on creating and marketing cutting-edge therapies for the treatment of progressive non-viral liver disorders.
The countries covered in the non alcoholic steatohepatitis (NASH) market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.